This is a continuing application for a Ph.D. (only) program in the Pharmacological Sciences. Graduate student trainees from Vanderbilt University or Meharry Medical College may be supported for up to two years of graduate training, generally years 2 and 3 of training. The first year of training in biomedical sciences at Vanderbilt University Medical Center is Interdisciplinary, and involves participation in an academic year long core curriculum. Students who select preceptors in the Pharmacological Sciences Training Program in May of their first year then begin the required course work for this graduate program. Program specific curriculum includes: Systems, Targets, and Drug Action (includes in vivo physiology, drug disposition, and principles of drug action); Receptors and Signal Transduction; Scientific Communications; and Biostatistics. In addition, students take at least six additional hours of elective courses to accommodate individual interests and needs. The curriculum for Meharry trainees is similar and cross registration agreements between Vanderbilt and Meharry results in Meharry trainees completing at least some of the above courses with Vanderbilt trainees. Research opportunities are available in several areas at both institutions: Receptor Mechanisms and Signal Transduction, Molecular mechanisms for Cellular Regulation, Neuropharmacology, Cardiovascular Pharmacology, Pharmacology of Arachidonic Acid Metabolites, and Drug Disposition and Pharmacokinetics. Course work is complemented by other important didactic experiences: weekly Journal Club; a student-invited annual Pharmacology Forum; an annual Department of Pharmacology Retreat for presenting upcoming research goals; and exchange programs between Vanderbilt and Meharry Medical College to strengthen the broad-based education of our students as well as to foster the careers of under-represented minorities in research. The training environment is further strengthened by emerging partnerships with the Lipscomb College of Pharmacy, the ability of trainees to participate in a Howard Hughes Medical Institute-funded Program in Molecular Medicine, and the presence of a highly successful, in-house Drug Discovery Program. Comprehensive qualifying examinations and defense of the dissertation proposal precedes dissertation research. After admission to candidacy for degree, dissertation committee meetings occur frequently to facilitate mentoring. The breadth of interest of the faculty, their international recognition and success in acquiring extramural peer-reviewed support, their understanding of the scientific process and an emphasis on scientific integrity make our program an outstanding environment for the training of independent scientists in the area of pharmacological sciences.

Public Health Relevance

Students are funded to provide training in the discipline of Pharmacology; the science of drug development and testing. Training includes coursework and original research in a laboratory. Scientists trained in this area perform important jobs in drug development in universities and industries, product safety, and regulatory affairs.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
4T32GM007628-39
Application #
9063582
Study Section
Training and Workforce Development Subcommittee - D (TWD)
Program Officer
Okita, Richard T
Project Start
1978-07-01
Project End
2018-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
39
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Other Health Professions
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37240
Yim, Yun Young; Zurawski, Zack; Hamm, Heidi (2018) GPCR regulation of secretion. Pharmacol Ther 192:124-140
Kharade, Sujay V; Kurata, Haruto; Bender, Aaron M et al. (2018) Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992. Mol Pharmacol 94:926-937
Fisher, Nicole M; Gogliotti, Rocco G; Vermudez, Sheryl Anne D et al. (2018) Genetic Reduction or Negative Modulation of mGlu7 Does Not Impact Anxiety and Fear Learning Phenotypes in a Mouse Model of MECP2 Duplication Syndrome. ACS Chem Neurosci 9:2210-2217
Bolus, W Reid; Peterson, Kristin R; Hubler, Merla J et al. (2018) Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab 8:86-95
Yuasa, Masato; Saito, Masanori; Molina, Cesar et al. (2018) Unexpected timely fracture union in matrix metalloproteinase 9 deficient mice. PLoS One 13:e0198088
Yang, Zhenlin; Han, Shuo; Keller, Max et al. (2018) Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor. Nature 556:520-524
Duncan, D'Anne S; Weiner, Rebecca L; Weitlauf, Carl et al. (2018) Ccl5 Mediates Proper Wiring of Feedforward and Lateral Inhibition Pathways in the Inner Retina. Front Neurosci 12:702
Crouch, Rachel D; Hutzler, J Matthew; Daniels, J Scott (2018) A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry. Xenobiotica 48:219-231
Kozek, Krystian A; Du, Yu; Sharma, Swagat et al. (2018) Discovery and Characterization of VU0529331, a Synthetic Small-Molecule Activator of Homomeric G Protein-Gated, Inwardly Rectifying, Potassium (GIRK) Channels. ACS Chem Neurosci :
Gogliotti, Rocco G; Fisher, Nicole M; Stansley, Branden J et al. (2018) Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M4 Muscarinic Receptor as a Novel Therapeutic Target. J Pharmacol Exp Ther 365:291-300

Showing the most recent 10 out of 178 publications